Pre-made Metelimumab benchmark antibody (Whole mAb, anti-TGFB1 therapeutic antibody, Anti-CED/DPD1/IBDIMDE/LAP Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-908
Anti-TGFB1 therapeutic antibody (Pre-made Metelimumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. It was dropped from further development in favour of fresolimumab, which was being developed by Genzyme as of 26.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Metelimumab Biosimilar, Whole Mab, Anti-Tgfb1 Antibody: Anti-CED/DPD1/IBDIMDE/LAP therapeutic antibody|
|CH1 Isotype||IgG4 - kappa|
|VD LC||IgG4 - kappa|
|Highest_Clin_Trial (Jan '20)|
|100% SI Structure|
|99% SI Structure|
|95-98% SI Structure|
|Companies||Genzyme Corp. (Cambridge MA USA) / Cambridge Antibody Technology (Cambridge UK)|